Short- and long-term changes in gene expression mediated by the activation of TLR9.

[1]  E. Kuramoto,et al.  Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. , 1992, Journal of immunology.

[2]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[3]  A. Krieg,et al.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. , 1996, Journal of immunology.

[4]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Hume,et al.  Macrophages ingest and are activated by bacterial DNA. , 1996, Journal of immunology.

[6]  D. Klinman,et al.  Contribution of CpG motifs to the immunogenicity of DNA vaccines. , 1997, Journal of immunology.

[7]  K. Heeg,et al.  Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. , 1997, European journal of immunology.

[8]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[9]  J. Sprent,et al.  Type I Interferon-mediated Stimulation of T Cells by CpG DNA , 1998, Journal of Experimental Medicine.

[10]  A. Rosenberg,et al.  Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. , 1998, Journal of immunology.

[11]  R. Vabulas,et al.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.

[12]  K. Heeg,et al.  CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. , 1998, Journal of immunology.

[13]  E. Gelfand,et al.  Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. , 1998, Journal of immunology.

[14]  J. Harty,et al.  CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. , 1998, Journal of immunology.

[15]  A. Krieg,et al.  Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Hültner,et al.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.

[17]  S. Stibitz,et al.  Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. , 1999, Journal of immunology.

[18]  S. Akira,et al.  Immune Cell Activation by Bacterial Cpg-DNA through Myeloid Differentiation Marker 88 and Tumor Necrosis Factor Receptor–Associated Factor (Traf)6 , 2000, The Journal of experimental medicine.

[19]  B. Holzmann,et al.  Increased Resistance Against Acute Polymicrobial Sepsis in Mice Challenged with Immunostimulatory CpG Oligodeoxynucleotides Is Related to an Enhanced Innate Effector Cell Response1 , 2000, The Journal of Immunology.

[20]  K. Ishii,et al.  CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. , 2000, Cellular immunology.

[21]  A. Aderem,et al.  Toll-like receptors in the induction of the innate immune response , 2000, Nature.

[22]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[23]  K. Ishii,et al.  Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells1 , 2001, The Journal of Immunology.

[24]  S. Akira,et al.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[26]  R. Vabulas,et al.  Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.

[27]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[28]  Inder M Verma,et al.  NF-kappaB regulation in the immune system. , 2002, Nature reviews. Immunology.

[29]  E. Raz,et al.  Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. , 2002, The Journal of allergy and clinical immunology.

[30]  M. Follettie,et al.  Regulation of gene expression in mouse macrophages stimulated with bacterial CpG‐DNA and lipopolysaccharide , 2002, Journal of leukocyte biology.

[31]  G. Hartmann,et al.  Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model1 , 2002, The Journal of Immunology.

[32]  S. Akira,et al.  Cutting Edge: A Novel Toll/IL-1 Receptor Domain-Containing Adapter That Preferentially Activates the IFN-β Promoter in the Toll-Like Receptor Signaling1 , 2002, The Journal of Immunology.

[33]  S. Halperin,et al.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.

[34]  G. Weiner,et al.  CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. , 2003, Current opinion in investigational drugs.

[35]  I. Mori,et al.  An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. , 2003, The Journal of general virology.

[36]  A. Kato,et al.  Interferon-α/β receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006 , 2003, BMC Immunology.

[37]  J. Lifson,et al.  CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from Leishmania Infection1 , 2003, The Journal of Immunology.

[38]  J. Vieira,et al.  Local Delivery of CpG Oligodeoxynucleotides Induces Rapid Changes in the Genital Mucosa and Inhibits Replication, but Not Entry, of Herpes Simplex Virus Type 2 , 2003, Journal of Virology.

[39]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[40]  J. Delattre,et al.  CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. , 2003, Frontiers in bioscience : a journal and virtual library.

[41]  邊見 弘明,et al.  A Toll-like receptor recognizes bacterial DNA , 2003 .

[42]  F. Schmitz,et al.  Transcriptional activation induced in macrophages by Toll‐like receptor (TLR) ligands: from expression profiling to a model of TLR signaling , 2004, European journal of immunology.

[43]  K. Ishii,et al.  CpG Oligodeoxynucleotides Improve the Survival of Pregnant and Fetal Mice following Listeria monocytogenes Infection , 2004, Infection and Immunity.

[44]  K. Heeg,et al.  Immunostimulatory CpG Oligonucleotides Reduce Tumor Burden after Intravesical Administration in an Orthotopic Murine Bladder Cancer Model , 2005, Tumor Biology.

[45]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[46]  T. Giese,et al.  B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides , 2005, Clinical Cancer Research.

[47]  F. Liew,et al.  Negative regulation of Toll-like receptor-mediated immune responses , 2005, Nature Reviews Immunology.

[48]  S. Klaschik,et al.  CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. , 2007, Molecular immunology.

[49]  A. Krieg.  Development of TLR9 agonists for cancer therapy. , 2007, The Journal of clinical investigation.

[50]  J. Leonard,et al.  Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma , 2007, Clinical Cancer Research.

[51]  A. Loubat,et al.  Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model. , 2008, International journal of molecular medicine.

[52]  R. Coffman,et al.  CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans , 2008, Clinical Cancer Research.

[53]  T. Krakauer.  Nuclear Factor-κB: Fine-Tuning a Central Integrator of Diverse Biologic Stimuli , 2008, International reviews of immunology.

[54]  K. Brown,et al.  TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. , 2008, Blood.

[55]  S. Klaschik,et al.  Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. , 2009, Molecular immunology.

[56]  S. Klaschik,et al.  Inductive and suppressive networks regulate TLR9‐dependent gene expression in vivo , 2009, Journal of leukocyte biology.